|
1
|
Bartel DP: MicroRNAs: target recognition
and regulatory functions. Cell. 136:215–233. 2009.
|
|
2
|
Xu P, Guo M and Hay BA: MicroRNAs and the
regulation of cell death. Trends Genet. 20:617–624. 2004.
|
|
3
|
Karp X and Ambros V: Developmental
biology. Encountering microRNAs in cell fate signaling. Science.
310:1288–1289. 2005.
|
|
4
|
Chen CZ, Li L, Lodish HF and Bartel DP:
MicroRNAs modulate hematopoietic lineage differentiation. Science.
303:83–86. 2004.
|
|
5
|
Poy MN, Eliasson L, Krutzfeldt J, et al: A
pancreatic islet-specific microRNA regulates insulin secretion.
Nature. 432:226–230. 2004.
|
|
6
|
Garzon R, Fabbri M, Cimmino A, Calin GA
and Croce CM: MicroRNA expression and function in cancer. Trends
Mol Med. 12:580–587. 2006.
|
|
7
|
Hermeking H: p53 enters the microRNA
world. Cancer Cell. 12:414–418. 2007.
|
|
8
|
Massano J, Regateiro FS, Januário G and
Ferreira A: Oral squamous cell carcinoma: review of prognostic and
predictive factors. Oral Surg Oral Med Oral Pathol Oral Radiol
Endod. 102:67–76. 2006.
|
|
9
|
Wu BH, Xiong XP, Jia J and Zhang WF:
MicroRNAs: new actors in the oral cancer scene. Oral Oncol.
47:314–319. 2011.
|
|
10
|
Li J, Huang H, Sun L, et al: MiR-21
indicates poor prognosis in tongue squamous cell carcinomas as an
apoptosis inhibitor. Clin Cancer Res. 15:3998–4008. 2009.
|
|
11
|
Wong TS, Liu XB, Wong BY, et al: Mature
miR-184 as potential oncogenic microRNA of squamous cell carcinoma
of tongue. Clin Cancer Res. 14:2588–2592. 2008.
|
|
12
|
Wong TS, Liu XB, Chung-Wai Ho A, et al:
Identification of pyruvate kinase type M2 as potential oncoprotein
in squamous cell carcinoma of tongue through microRNA profiling.
Int J Cancer. 123:251–257. 2008.
|
|
13
|
Jiang L, Liu X, Kolokythas A, et al:
Downregulation of the Rho GTPase signaling pathway is involved in
the microRNA-138-mediated inhibition of cell migration and invasion
in tongue squamous cell carcinoma. Int J Cancer. 127:505–512.
2010.
|
|
14
|
Liu Y, Chen Q, Song Y, et al: MicroRNA-98
negatively regulates IL-10 production and endotoxin tolerance in
macrophages after LPS stimulation. FEBS Lett. 585:1963–1968.
2011.
|
|
15
|
Wang QQ, Li H, Oliver T, et al: Integrin
beta 1 regulates phagosome maturation in macrophages through Rac
expression. J Immunol. 180:2419–2428. 2008.
|
|
16
|
Yellen P, Saqcena M, Salloum D, et al:
High-dose rapamycin induces apoptosis in human cancer cells by
dissociating mTOR complex 1 and suppressing phosphorylation of
4E-BP1. Cell Cycle. 10:3948–3956. 2011.
|
|
17
|
Chen CH and Sarbassov dos D: The mTOR
(mammalian target of rapamycin) kinase maintains integrity of mTOR
complex 2. J Biol Chem. 286:40386–40394. 2011.
|
|
18
|
Liao YM, Kim C and Yen Y: Mammalian target
of rapamycin and head and neck squamous cell carcinoma. Head Neck
Oncol. 3:222011.
|
|
19
|
Chang KY, Tsai SY, Wu CM, et al: Novel
phosphoinositide 3-kinase/mTOR dual inhibitor, NVP-BGT226, displays
potent growth-inhibitory activity against human head and neck
cancer cells in vitro and in vivo. Clin Cancer Res. 17:7116–7126.
2011.
|
|
20
|
Yang CJ, Shen WG, Liu CJ, et al: miR-221
and miR-222 expression increased the growth and tumorigenesis of
oral carcinoma cells. J Oral Pathol Med. 40:560–566. 2011.
|
|
21
|
Wiklund ED, Gao S, Hulf T, et al: MicroRNA
alterations and associated aberrant DNA methylation patterns across
multiple sample types in oral squamous cell carcinoma. PLoS One.
6:e278402011.
|
|
22
|
Yang CC, Hung PS, Wang PW, et al: miR-181
as a putative biomarker for lymph-node metastasis of oral squamous
cell carcinoma. J Oral Pathol Med. 40:397–404. 2011.
|
|
23
|
Yu CC, Chen YW, Chiou GY, et al: MicroRNA
let-7a represses chemoresistance and tumourigenicity in head and
neck cancer via stem-like properties ablation. Oral Oncol.
47:202–210. 2011.
|
|
24
|
Yu ZW, Zhong LP, Ji T, et al: MicroRNAs
contribute to the chemoresistance of cisplatin in tongue squamous
cell carcinoma lines. Oral Oncol. 46:317–322. 2010.
|
|
25
|
Lo WL, Yu CC, Chiou GY, et al:
MicroRNA-200c attenuates tumour growth and metastasis of
presumptive head and neck squamous cell carcinoma stem cells. J
Pathol. 223:482–495. 2010.
|
|
26
|
Gomes CC and Gomez RS: MicroRNA and oral
cancer: future perspectives. Oral Oncol. 44:910–914. 2008.
|
|
27
|
Coutte L, Dreyer C, Sablin MP, Faivre S
and Raymond E: PI3K-AKT-mTOR pathway and cancer. Bull Cancer.
99:173–180. 2012.(In French).
|
|
28
|
Seeliger H, Guba M, Kleespies A, Jauch KW
and Bruns CJ: Role of mTOR in solid tumor systems: a therapeutical
target against primary tumor growth, metastases, and angiogenesis.
Cancer Metastasis Rev. 26:611–621. 2007.
|
|
29
|
Aissat N, Le Tourneau C, Ghoul A, et al:
Antiproliferative effects of rapamycin as a single agent and in
combination with carboplatin and paclitaxel in head and neck cancer
cell lines. Cancer Chemother Pharmacol. 62:305–313. 2008.
|
|
30
|
Fingar DC, Richardson CJ, Tee AR, et al:
mTOR controls cell cycle progression through its cell growth
effectors S6K1 and 4E-BP1/eukaryotic translation initiation factor
4E. Mol Cell Biol. 24:200–216. 2004.
|
|
31
|
Grewe M, Gansauge F, Schmid RM, Adler G
and Seufferlein T: Regulation of cell growth and cyclin D1
expression by the constitutively active FRAP-p70s6K pathway in
human pancreatic cancer cells. Cancer Res. 59:3581–3587. 1999.
|
|
32
|
Sun D, Lee YS, Malhotra A, et al: miR-99
family of MicroRNAs suppresses the expression of prostate-specific
antigen and prostate cancer cell proliferation. Cancer Res.
71:1313–1324. 2011.
|
|
33
|
Li D, Liu X, Lin L, et al: MicroRNA-99a
inhibits hepatocellular carcinoma growth and correlates with
prognosis of patients with hepatocellular carcinoma. J Biol Chem.
286:36677–36685. 2011.
|
|
34
|
Yamada H, Yanagisawa K, Tokumaru S, et al:
Detailed characterization of a homozygously deleted region
corresponding to a candidate tumor suppressor locus at 21q11-21 in
human lung cancer. Genes Chromosomes Cancer. 47:810–818. 2008.
|
|
35
|
Nam EJ, Yoon H, Kim SW, et al: MicroRNA
expression profiles in serous ovarian carcinoma. Clin Cancer Res.
14:2690–2695. 2008.
|
|
36
|
Catto JW, Miah S, Owen HC, et al: Distinct
microRNA alterations characterize high- and low-grade bladder
cancer. Cancer Res. 69:8472–8481. 2009.
|
|
37
|
Hermeking H: The miR-34 family in cancer
and apoptosis. Cell Death Differ. 17:193–199. 2010.
|
|
38
|
He L, Thomson JM, Hemann MT, et al: A
microRNA polycistron as a potential human oncogene. Nature.
435:828–833. 2005.
|
|
39
|
Minor J, Wang X, Zhang F, et al:
Methylation of microRNA-9 is a specific and sensitive biomarker for
oral and oropharyngeal squamous cell carcinomas. Oral Oncol.
48:73–78. 2012.
|
